Risk factors, features of clinical course and treatment approaches in aged patients with cerebral stroke

Close metadata

Recommended articles:

Cerebrolysin as an early add-on to reperfusion therapy: heterogeneous treatment effect analysis in ischemic stroke patients with varying risk of hemorrhagic transformation. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):55-66

Efficacy of Mexidol in combination with cerebral revascularization in the treatment of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):67-74

Promising approaches to the pathogenetic therapy of amyotrophic lateral sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):13-21

Long-term follow-up of adult patients with serial and status course of epileptic seizures. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):63-68

Cognitive impairment in cerebrovascular diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):12-16

Diagnostic approaches to assessing mild behavioral impairment in patients with mild cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):49-55

Efficacy and safety of choline alfoscerate in the preventive therapy of dementia in elderly patients with Mild Cognitive Impairment: a three-year prospective comparative study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):92-99

Algorithms for the diagnosis and treatment of cognitive impairment and dysphagia in stroke patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):100-107

Traumatic damage to the diaphragm in children. Pirogov Russian Journal of Surgery. 2024;(4):64-68

Relapse of primary mediastinal B-cell lymphoma with isolated central nervous system involvement: risk factors and search for personalized therapy. P.A. Herzen Journal of Oncology. 2024;(2):39-45

Keywords:

stroke

therapy

aged patients

Authors:

Putilina M.V.

Kafedra nevrologii fakulteta usovershenstvovaniia vracheĭ Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

List of references:

Rumyantseva S.A., Stupin V.A., Afanas'ev V.V. Vtoroi shans (Sovremennye predstavleniya o neiroprotektsii). M: Meditsinskaya kniga 2011; 174.
Tanashyan M.M., Lagoda O.V., Fedin P.A. i dr. Antioksidantnaya terapiya khronicheskikh tserebrovaskulyarnykh zabolevanii. Rus med zhurn 2010; 18: 8.
Shmyrev V.I., Bobrova T.A. Tserebrovaskulyarnye narusheniya u bol'nykh pozhilogo vozrasta s arterial'noi gipertenziei. Klinicheskaya gerontologiya 2001; 7: 10: 7-10.
Yakhno N.N., Damulin I.V., Bibikov L.G. Khronicheskaya sosudistaya mozgovaya nedostatochnost' u pozhilykh: kliniko-komp'yuterno-tomograficheskie sopostavleniya. Klinicheskaya gerontologiya 1995; 1: 32-36.
Adams H.P. Jr, del Zoppo G., Alberts M.J. et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38: 1655-1711.
Adams R.J., Albers G., Alberts M.J. et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008; 39: 1647-1652.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
Antithrombotic TrialistsCollaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
Chalmers J., Todd A., Chapman N. et al. International Society of Hypertension (ISH): statement on blood pressure lowering and stroke prevention. J Hypertens 2003; 21: 651-663.
Clarke R., Emberson J.R., Parish S. et al. Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality in older men. Arch Intern Med 2007; 167: 1373-1378.
Curb J.D., Abbott R.D., Rodriguez B.L. et al. High density lipoprotein cholesterol and the risk of stroke in elderly men: the Honolulu Heart Program. Am J Epidemiol 2004; 160: 150-157.
Dominguez C., Delgado P. et al. Oxidative stress after thrombolysis-induced reperfusion in human stroke. Stroke 2010; 5-6: 19/20: 51-61.
Green A.R. Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly. Br J Pharmacol 2008; 153: Suppl 1: 325-338.
Gutierrez M., Tejedor E.D., de Lecinana M.A. et al. Thrombolysis and neuroprotection in cerebral ischemia. Cerebrovasc Dis 2006; 21: Suppl 2: 118-126.
Law M.R., Wald N.J., Morris J.K., Jordan R.E. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427.
Lawlor D.A., Whincup P., Emberson J.R. et al. The challenge of secondary prevention for coronary heart disease in older patients: findings from the British Womens Heart and Health Study and the British Regional Heart Study. Fam Pract 2004; 21: 582-586.
Ly J.V., Zavala J.A., Donnan G.A. Neuroprotection and thrombolysis: combination therapy in acute ischaemic stroke. Expert Opin Pharmacother 2006; 7: 12: 1571-1581.
Marini C., Baldassarre M., Russo T. et al. Burden of first-ever ischemic stroke in the oldest old: evidence from a population-based study. Neurology 2004; 62: 77-81.
Quilliam B.J., Lapane K.L. Clinical correlates and drug treatment of residents with stroke in long-term care. Stroke 2001; 32: 1385-1393.
Samsa G.P., Matchar D.B., Goldstein L. et al. Utilities for major stroke: results from a survey of preferences among persons at increased risk for stroke. Am Heart J 1998; 136: 703-713.
Sanossian N., Ovbiagele B. Prevention and management of stroke in very elderly patients. Lancet Neurol 2009; 8: 1031-1041.
Saposnik G., Cote R., Phillips S. et al. Stroke outcome in those over 80: a multicenter cohort study across Canada. Stroke 2008; 39: 2310-2317.
SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
Simpson C.R., Wilson C., Hannaford P.C., Williams D. Evidence for age and sex differences in the secondary prevention of stroke in Scottish primary care. Stroke 2005; 36: 1771-1775.
Strandberg T.E., Pitkala K., Kulp S., Tilvis R.S. Use of cardiovascular drugs by home-dwelling coronary patients aged 75 years and older. A population-based cross-sectional survey in Helsinki, Finland. Eur J Clin Pharmacol 2001; 57: 513-516.
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-559.
Turnbull F., Neal B., Ninomiya T. et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121-1123.
Volpato S., Maraldi C., Ble A. et al. Prescription of antithrombotic therapy in older patients hospitalized for transient ischemic attack and ischemic stroke: the GIFA study. Stroke 2004; 35: 913-917.
Weycker D., Edelsberg J., Vincze G. et al. Blood pressure control in patients initiating antihypertensive therapy. Ann Pharmacother 2008; 42: 169-176.
Williams D., Bennett K., Feely J. Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care. Br J Clin Pharmacol 2003; 55: 604-608.
Williams M.A., Fleg J.L., Ades P.A. et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients > or = 75 years of age): an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 2002; 105: 1735-1743.

Close metadata